Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434024 | 0.87 | GRIN2B (0.40) | ALKGRIN2B | |
| SCHEMBL21452690 | 0.86 | CHEK1 (0.44) | ALKCHEK1 | |
| SCHEMBL21433962 | 0.84 | SMPD3 (0.42) | SIK1SIK2SIK3PDE4DGRIN2B | |
| SCHEMBL21452612 | 0.83 | CHEK1 (0.47) | CHEK1GRIN2B | |
| SCHEMBL21433937 | 0.76 | SMPD3 (0.43) | SIK1SIK2SIK3PDE4DGRIN2B | |
| SCHEMBL21452667 | 0.74 | ENPP2 (0.48) | CHEK1 | |
| SCHEMBL21434074 | 0.74 | CYP2C9 (0.38) | — | |
| SCHEMBL21433904 | 0.74 | PDE4D (0.41) | SIK1SIK2SIK3PDE4D | |
| SCHEMBL27106846 | 0.72 | WNT3A (0.52) | ALKCHEK1 | |
| SCHEMBL21434068 | 0.72 | SMPD3 (0.52) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | ALK 1623/4885CHEK1 4071/4885SIK1 3593/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | ALK 1623/4885CHEK1 4071/4885SIK1 3593/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | ALK 1773/4885CHEK1 4154/4885SIK1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.